For many people, these medications reduce hunger, slow gastric emptying, and make it easier to maintain a calorie deficit
doi: 10.1007/s00125-018-4729-5 17 American Diabetes Association Professional Practice CommitteeDrazninBArodaVRBakrisGBensonGBrownFMet al
Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
Microdosing gets credited with everything from effortless maintenance to quieter side effects to some vague promise of metabolic renewal, and most of what's written about it is either selling something or copied from something that was
10.1111/anae.16306 (a U.K
A standard-dose semaglutide plan usually starts low and increases gradually
